{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lipsitz YY"],"funding":["Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada","Canada Research Chairs","CIHR"],"pagination":["6369-6374"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6016797"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["115(25)"],"pubmed_abstract":["The development of cell-based therapies to replace missing or damaged tissues within the body or generate cells with a unique biological activity requires a reliable and accessible source of cells. Human pluripotent stem cells (hPSC) have emerged as a strong candidate cell source capable of extended propagation in vitro and differentiation to clinically relevant cell types. However, the application of hPSC in cell-based therapies requires overcoming yield limitations in large-scale hPSC manufacturing. We explored methods to convert hPSC to alternative states of pluripotency with advantageous bioprocessing properties, identifying a suspension-based small-molecule and cytokine combination that supports increased single-cell survival efficiency, faster growth rates, higher densities, and grea"],"journal":["Proceedings of the National Academy of Sciences of the United States of America"],"pubmed_title":["Modulating cell state to enhance suspension expansion of human pluripotent stem cells."],"pmcid":["PMC6016797"],"funding_grant_id":["CGS-D","Tier 1"],"pubmed_authors":["Zandstra PW","Yin T","Hanna JH","Lipsitz YY","Woodford C"],"additional_accession":[]},"is_claimable":false,"name":"Modulating cell state to enhance suspension expansion of human pluripotent stem cells.","description":"The development of cell-based therapies to replace missing or damaged tissues within the body or generate cells with a unique biological activity requires a reliable and accessible source of cells. Human pluripotent stem cells (hPSC) have emerged as a strong candidate cell source capable of extended propagation in vitro and differentiation to clinically relevant cell types. However, the application of hPSC in cell-based therapies requires overcoming yield limitations in large-scale hPSC manufacturing. We explored methods to convert hPSC to alternative states of pluripotency with advantageous bioprocessing properties, identifying a suspension-based small-molecule and cytokine combination that supports increased single-cell survival efficiency, faster growth rates, higher densities, and grea","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Jun","modification":"2026-05-06T06:47:31.249Z","creation":"2019-03-26T23:43:48Z"},"accession":"S-EPMC6016797","cross_references":{"pubmed":["29866848"],"doi":["10.1073/pnas.1714099115"]}}